Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Angewandte Chemie (International Ed. in English)|June 29, 2019
Ethynylphosphonamidates for the Rapid and Cysteine-Selective Generation of Efficacious Antibody-Drug ConjugatesMarc-André Kasper, Andreas Stengl, Philipp Ochtrop, et al.
Chemical Science|May 17, 2017
Broad substrate tolerance of tubulin tyrosine ligase enables one-step site-specific enzymatic protein labelingDominik Schumacher, Oliver Lemke, Jonas Helma, et al.
Chembiochem : a European Journal of Chemical Biology|October 30, 2019
N-Hydroxysuccinimide-Modified Ethynylphosphonamidates Enable the Synthesis of Configurationally Defined Protein ConjugatesMarc-André Kasper, Marcus Gerlach, Anselm F L Schneider, et al.
Molecular Microbiology|November 14, 2012
PomZ, a ParA-like protein, regulates Z-ring formation and cell division in Myxococcus xanthusAnke Treuner-Lange, Kryssia Aguiluz, Chris van der Does, et al.
Angewandte Chemie (International Ed. in English)|March 5, 2019
Cysteine-Selective Phosphonamidate Electrophiles for Modular Protein BioconjugationsMarc-André Kasper, Maria Glanz, Andreas Stengl, et al.
Molecular Cancer Therapeutics|October 13, 2023
Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody-Drug ConjugatesSaskia Schmitt, Paul Machui, Isabelle Mai, et al.
Molecular Cancer Therapeutics|August 20, 2025
TUB-010, a novel anti-CD30 antibody-drug conjugate based on Tub-tag technology, widens the therapeutic window by reducing toxicity while maintaining high efficacyMarcus Gerlach, Saskia Schmitt, Philipp Cyprys, et al.
Nature Chemistry|July 30, 2017
Cell-permeable nanobodies for targeted immunolabelling and antigen manipulation in living cellsHenry D Herce, Dominik Schumacher, Anselm F L Schneider, et al.
Journal of the American Chemical Society|May 5, 2025
Orthogonal Site-Specific Dual Bioconjugation of Aryl and Alkyl ThiolsMark A R de Geus, Christian E Stieger, Jan Vincent V Arafiles, et al.
Molecular Cancer Therapeutics|July 16, 2025
TUB-040, a homogenous and hydrophilic NaPi2b-targeting ADC with stably linked exatecan, exhibits long-lasting anti-tumor activity and a well-tolerated safety profileAnnette M Vogl, Saskia Schmitt, Isabelle Mai, et al.
Pageof 4